News
PolyPid Announces Scheduling of Type D Meeting with U.S. FDA to Discuss SHIELD I Phase 3 Results and Regulatory Pathway for D-PLEX for the Prevention of Surgical Site Infections in Abdominal Colorectal Surgery
Meeting Scheduled for January 2023 PolyPid Recently Provided FDA with Currently Available Data from Completed SHIELD I Phase 3 Study in Advance of Meeting PETACH TIKVA, Israel, Dec. 12, 2022 -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage...
PolyPid Announces Receipt of Nasdaq Minimum Bid Price Notification
PETACH TIKVA, Israel, Dec. 09, 2022 -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced it has received a written notice (the "Notice") from Nasdaq Stock Market LLC ("Nasdaq")...
PolyPid Announces Presentation of Phase 2 D-PLEX Clinical Data at the First Triennial Meeting of the International Orthopaedic Trauma Association
D-PLEX Infection Prevention Efficacy in Patients with Increased Risk for Surgical Wound Infections Including Multi-Drug Resistant Organisms (MDROs) will be Presented During a Podium PresentationPETACH TIKVA, Israel, Nov. 29, 2022 -- PolyPid Ltd. (Nasdaq: PYPD)...
PolyPid Provides Corporate Update and Reports Third Quarter 2022 Financial Results
Company Intends to Meet with U.S. and EU Regulatory Authorities to Discuss Data from SHIELD I Phase 3 Study and Regulatory Pathway for D-PLEX100 in First Quarter of 2023 Implemented a Cost Reduction Plan, Including a 20% Decrease in Headcount Across All Departments...
PolyPid to Report Third Quarter 2022 Financial Results and Operational Highlights on November 9, 2022
PETACH TIKVA, Israel, Oct. 26, 2022 -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report its third quarter 2022 financial results and operational highlights...
PolyPid Announces Cost Reduction Plan
Reduction of Approximately 20% in Organization Headcount Company Expects to Extend Cash Runway into Q3 2023 PolyPid Intends to Discuss Regulatory Pathway for D-PLEX100 for Prevention of Surgical Site Infections in Abdominal Surgery with U.S. and EU Regulatory...
PolyPid Announces Peer-Reviewed Publication of Phase 2 Clinical Trial Results for D-PLEX in the Prevention of Surgical Site Infections in Abdominal Surgery
Intends to discuss the Clinical Outcomes and Next Steps for D-PLEX100 for the Prevention of SSIs in Abdominal Surgery with the FDA and the EU Regulatory Authorities in Q1 2023 PETACH TIKVA, Israel, Sept. 19, 2022 -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the...
PolyPid Announces Presentation of Phase 2 D-PLEX Clinical Data at the European Society for Coloproctology Scientific Conference
Efficacy Data of D-PLEX100 in the Prevention of Post-Abdominal Surgery Incisional Infection will be Presented During a Podium Presentation PETACH TIKVA, Israel, Sept. 12, 2022 -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company...
PolyPid Announces Top-line Results of Phase 3 SHIELD I Trial of D-PLEX for the Prevention of Surgical Site Infections in Abdominal Surgery
SHIELD I Study did not Achieve its Primary Endpoint of Reduction in Surgical Site Infections and Mortality In an FDA Requested Pre-specified Subgroup Analysis in Subjects with Incision Lengths over 20 centimeters (n=423), D-PLEX100 + SoC Achieved a Statistically...
PolyPid Announces Presentation at the 2022 Military Health System Research Symposium
Efficacy Data of D-PLEX100 in reduction of Surgical Site Infection in Surgical Trauma Injuries will be Presented During a Podium Presentation PETACH TIKVA, Israel, Aug. 30, 2022 -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma...